52North Selected to join the Cedars Sinai Accelerator Program

The Cedars-Sinai Accelerator's ninth class welcomes ten global health-tech companies, among them, 52North, based in Cambridge, U.K.

During the three-month program, the companies receive hands-on experience and mentorship from Cedars-Sinai's experts to refine the practical applications of their products. Each participant gains a $100,000 investment from Cedars-Sinai. After completion, they present their progress at a Demo Day to potential investors, mentors, and media.

The spotlight falls on 52North, a U.K. firm developing Neutrocheck®, a device to monitor neutropenic sepsis risk in chemotherapy patients outside hospitals. Neutrocheck facilitates at-home testing through a simple blood pinprick.

This accelerator class aligns with Cedars-Sinai's mission to revolutionize healthcare and research beyond Los Angeles, offering strategic and operational insights at the outset of development. Through mentoring, investment, and innovation, the accelerator program cultivates healthcare advancements to improve patient care globally.

Read the Full Article on the Cedars Sinai Site